The present invention comprises methods and compositions for the reductionof oxalate in humans, animals and plants. For example, the invention providesmethods and compositions for the delivery of one or more oxalate-reducing pharmaceuticalcompositions to the intestinal tracts of persons and animals. The methods andcompositions can be used in treating and preventing oxalate-related conditions.A composition of the invention comprises an oral delivery vehicle comprisingan oxalate degrading bacteria, one or more cryopreserving agents and one or moreexcipients. A composition of the invention is enteric coated and has a suitableshelf-life and acceptable properties to avoid negative impact from gastricfluid when it is orally administered.
